{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:31:42Z","timestamp":1761154302174},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":692,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2000,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>: The efficacy of proton pump inhibitor based triple therapy in patients from South\u2010East Asia, where metronidazole resistance is reportedly high, has not been formally assessed in randomized, multicentre trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>: To compare the eradication rates of <jats:italic>Helicobacter pylori,<\/jats:italic> ulcer healing rates and side\u2010effects of three regimens of omeprazole triple therapy in patients with duodenal ulcer from South\u2010East Asia and to study the impact of metronidazole resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>: A single blind, randomized parallel group, comparative multicentre study. A total of 246 patients from 15 centres in four South\u2010East Asian countries were randomized to receive OAC (omeprazole 20\u2003mg b.d., amoxycillin 1\u2003g b.d., clarithromycin 500\u2003mg b.d.), OAM (omeprazole 20\u2003mg b.d., amoxycillin 1\u2003g b.d., metronidazole 400\u2003mg b.d.) or OMC (omeprazole 20\u2003mg b.d., metronidazole 400\u2003mg b.d., clarithromycin 500\u2003mg b.d.) for 7\u2003days. After triple therapy, the patients were further randomized to receive either omeprazole or placebo for 7\u2003days. Upper gastrointestinal endoscopy was performed before treatment and 4\u2003weeks after treatment. Biopsies for culture and for histopathological examination for <jats:italic>H. pylori<\/jats:italic> were taken from corpus and antrum before treatment and 4\u2003weeks after treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>: The eradication rates were intention\u2010to\u2010treat\/per protocol (95% CI): OAC 87% (79\u201394%)\/94% (89\u2013100%); OAM 80% (70\u201389%)\/91% (83\u201398%); OMC 85% (77\u201393%)\/94% (88\u2013100%). The difference in eradication rates between the three groups was not statistically significant (<jats:italic>P<\/jats:italic>=0.419). Pre\u2010treatment metronidazole resistance, was found in 34% of isolates and was a significant prognostic factor in patients receiving OAM (odds ratio 5.26) but not in patients receiving OAC or OMC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>: All three treatment regimens were safe, well tolerated and highly effective for eradication of <jats:italic>H. pylori<\/jats:italic> and ulcer healing. Pre\u2010treatment metronidazole resistance reduced the efficacy of OAM but did not affect the efficacy of OMC.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2000.00691.x","type":"journal-article","created":{"date-parts":[[2003,3,10]],"date-time":"2003-03-10T22:40:52Z","timestamp":1047336052000},"page":"225-231","source":"Crossref","is-referenced-by-count":37,"title":["Triple therapy in the eradication of <i>Helicobacter pylori<\/i> in patients with duodenal ulcer disease: results of a multicentre study in South\u2010East Asia"],"prefix":"10.1111","volume":"14","author":[{"family":"Fock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Chelvam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"THE SOUTH\u2010EAST ASIA MULTICENTRE STUDY GROUP","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1991.tb01453.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1994.03520010077036","article-title":"Helicobacter pylori in peptic ulcer disease","volume":"272","author":"NIH Consensus Development Panel","year":"1994","journal-title":"J Am Med Assoc"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199305000-00005"},{"key":"e_1_2_6_5_2","unstructured":"IARC.Schistosomes. Liver flukes andHelicobacter pylori. In: IARC Monographs on the Valuation of Carcinogenic Risks to Humans Vol. 61. Geneva: WHO publications 1994: pp. 177\u2013240."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1998.tb00537.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00027.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.1.8"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)80022-4"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91301-P"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1997.tb00491.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00003.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007509"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1991.tb01468.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199409000-00004"},{"key":"e_1_2_6_16_2","first-page":"1185","article-title":"One week therapy with omeprazole, clarithromycin and metronidazole or Oridazole, followed by 3 weeks treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer","volume":"9","author":"Tzivras M","year":"1997","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.5.675"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00009.x"},{"key":"e_1_2_6_19_2","first-page":"39","article-title":"Primary and secondary metronidazole resistant Helicobacter pylori in an urban Asian Population","volume":"2","author":"Teo EK","year":"1996","journal-title":"Gut"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.6.735"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70119-8"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018882804607"},{"key":"e_1_2_6_23_2","first-page":"248","article-title":"Highly effective twice daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?","volume":"92","author":"Lerang F","year":"1997","journal-title":"Am J Gastroenterol"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00691.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00691.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2000.00691.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:01:10Z","timestamp":1697425270000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2000.00691.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["10.1046\/j.1365-2036.2000.00691.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2000.00691.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"type":"print","value":"0269-2813"},{"type":"electronic","value":"1365-2036"}],"subject":[],"published":{"date-parts":[[2000,2]]}}}